# Japan Long-term Safety for Tiotropium Plus Olodaterol

> **NCT01536262** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 122 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium + Olodaterol
- **DEVICE:** Respimat
- **DRUG:** Tiotropium + Olodaterol
- **DRUG:** Olodaterol
- **DEVICE:** Respimat
- **DEVICE:** Respimat

## Key facts

- **NCT ID:** NCT01536262
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2015-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01536262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01536262, "Japan Long-term Safety for Tiotropium Plus Olodaterol". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01536262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*